Cara Care

The company operates in the digital therapeutics market, targeting people suffering from conditions such as Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD), and Gastroesophageal Reflux Disease (GERD). Cara Care's primary offering is a mobile application that provides a personalized, multi-therapy program for users. This digital therapeutic, also known as a DiGA (Digitale Gesundheitsanwendung) in Germany, is available by prescription and is reimbursed by all German statutory health insurances.

The Cara Care app delivers a comprehensive program that includes nutritional therapy, psychological support from certified experts, and a digital diary to track symptoms, diet, and well-being. This integrated approach aims to help users identify trigger foods and manage their symptoms more effectively over the long term. The business model is centered on prescription-based reimbursement from health insurance providers, positioning it as a recognized medical device. In addition to its services in Germany, the company also offers a version of its application in the United States.

Cara Care has secured significant funding to support its growth, including a $7 million Series B round led by Dr. Schär AG and a previous $2 million financing round involving Johnson & Johnson Innovation. These investments have enabled the company to expand its offerings and conduct clinical research to validate the effectiveness of its digital therapies. One study, for instance, demonstrated the app's efficacy in reducing symptoms for individuals with IBS.